Looking up 'mounjaro pil'? Here's what the medicine actually is

You typed 'pil', here's what Mounjaro actually is

A fair few people land on this page after typing quickly on a phone, or because they've seen 'pil' used as shorthand in online communities. Either way, the medicine they're thinking of is an injection. Each Mounjaro KwikPen contains a four-week supply (one dose per week) and is administered subcutaneously into the abdomen, thigh, or upper arm. Rotating the injection site each week helps avoid irritation.

There is no Mounjaro tablet or capsule available in the UK. The closest thing to an oral GLP-1 weight-loss medicine currently is the newly approved Wegovy tablet (oral semaglutide), which received MHRA authorisation on 11 June 2026, but that is a different active ingredient. If you'd like to understand how the two compare, our Mounjaro versus the oral pill page walks through the differences plainly. For the full picture on tirzepatide as a compound, the tirzepatide overview covers the mechanism in more detail, and if you want the official patient information leaflet for the medicine, our tirzepatide PIL page has everything set out clearly.

The NHS medicines page for tirzepatide is a reliable first stop for patient-level information on how it works and what side effects to watch for.

How the weekly pen works in practice

Mounjaro mimics two gut hormones released after eating: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Activating both pathways together slows gastric emptying, signals the brain that you're full sooner, and helps regulate blood sugar. Because it acts on two receptors rather than one, trial data has generally shown greater average weight reduction than single-pathway GLP-1 medicines.

In SURMOUNT-1, a 72-week trial involving thousands of adults with obesity and no diabetes, participants on the highest dose saw average body-weight reductions of around 20–21%. The trial was published in the New England Journal of Medicine and formed the evidence base for NICE's recommendation of tirzepatide, issued in December 2024 (NICE technology appraisal TA1026). Results from your own treatment would depend on your starting weight, the dose you reach, and the lifestyle changes you make alongside it, a prescriber can put that in context for you.

Treatment starts at 2.5 mg. That first pen's job is letting your body settle in, particularly your digestive system, before the dose increases. Most people move up every four weeks, guided by their prescriber, to the highest dose they tolerate well. Timing matters: our guide on when to take Mounjaro explains the weekly injection routine and what to do if a dose falls awkwardly.

Who the medicine is licensed for, and what 'suitable' actually means

We know that waiting to find out whether you even qualify can feel like yet another hurdle. The licensed threshold in the UK is a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, things like high blood pressure, raised cholesterol, type 2 diabetes, prediabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But a number on a scale is never the whole picture. A prescriber considers your medical history, current medicines, and any contraindications before deciding whether Mounjaro is appropriate for you specifically.

Some people ask whether they can take supplements alongside the pen. That's a reasonable question, if it's relevant to you, our page on taking berberine with Mounjaro addresses one of the more common combinations. For a broader sense of how the weight-loss treatment options available through nume fit together, that page gives a clear overview. Checking how the private cost of treatment breaks down is also something people think about early on; our Mounjaro cost in the UK page is honest about what legitimate private pricing looks like. And if you want to know more about the clinical team deciding on suitability, our lead prescriber's profile is worth a read.